Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
Invivyd (Nasdaq: IVVD) has appointed venture capitalist Ajay Royan to its Board of Directors. Royan, founder of Mithril Capital, is a significant long-term stockholder who led the 2022 shareholder action focusing Invivyd on protecting against viral infectious diseases, particularly COVID-19.
The company aims to advance its monoclonal antibody technology platform beyond COVID-19 prevention into more scalable, higher-value medicines. The platform specifically targets vulnerable populations including cancer patients, organ transplant recipients, immunodeficient individuals, and those on immunosuppressive therapies.
Royan emphasizes the need to address endemic diseases affecting vulnerable Americans with the same urgency as Operation Warp Speed, highlighting the limitations of vaccines and the impact of long COVID on these communities.
Invivyd (Nasdaq: IVVD) ha nominato il capitalista di rischio Ajay Royan nel suo Consiglio di Amministrazione. Royan, fondatore di Mithril Capital, è un importante azionista a lungo termine che ha guidato l'azione dei soci nel 2022, concentrando Invivyd sulla protezione contro le malattie infettive virali, in particolare il COVID-19.
L'azienda mira a sviluppare la sua piattaforma tecnologica degli anticorpi monoclonali oltre la prevenzione del COVID-19, verso medicinali più scalabili e di maggior valore. La piattaforma si rivolge specificamente a popolazioni vulnerabili, tra cui pazienti oncologici, riceventi trapianti d'organo, individui immunodeficienti e coloro che seguono terapie immunosoppressive.
Royan sottolinea la necessità di affrontare le malattie endemiche che colpiscono gli americani vulnerabili con la stessa urgenza di Operation Warp Speed, evidenziando i limiti dei vaccini e l'impatto del long COVID su queste comunità.
Invivyd (Nasdaq: IVVD) ha nombrado al capitalista de riesgo Ajay Royan en su Junta Directiva. Royan, fundador de Mithril Capital, es un importante accionista a largo plazo que lideró la acción de los accionistas en 2022, enfocando a Invivyd en la protección contra enfermedades infecciosas virales, especialmente COVID-19.
La empresa tiene como objetivo avanzar su plataforma de tecnología de anticuerpos monoclonales más allá de la prevención del COVID-19 hacia medicamentos más escalables y de mayor valor. La plataforma se dirige específicamente a poblaciones vulnerables, incluidos pacientes con cáncer, receptores de trasplantes de órganos, individuos inmunodeprimidos y aquellos en terapias inmunosupresoras.
Royan enfatiza la necesidad de abordar las enfermedades endémicas que afectan a los estadounidenses vulnerables con la misma urgencia que la Operación Warp Speed, destacando las limitaciones de las vacunas y el impacto del long COVID en estas comunidades.
Invivyd (Nasdaq: IVVD)는 벤처 자본가 Ajay Royan을 이사회에 임명했습니다. Royan은 Mithril Capital의 설립자로, 2022년 주주 행동을 이끌며 Invivyd가 COVID-19를 포함한 바이러스 감염 질병 보호에 집중하게 만든 중요한 장기 주주입니다.
회사는 단클론 항체 기술 플랫폼을 COVID-19 예방을 넘어 더 확장 가능하고 가치가 높은 의약품으로 발전시키는 것을 목표로 하고 있습니다. 이 플랫폼은 암 환자, 장기 이식 수혜자, 면역 결핍 개인 및 면역 억제 요법을 받는 사람들을 포함한 취약한 인구를 특히 겨냥합니다.
Royan은 취약한 미국인들에게 영향을 미치는 풍토병을 해결해야 할 필요성을 Operation Warp Speed와 같은 긴급성으로 강조하며, 백신의 한계와 이러한 커뮤니티에서의 롱 COVID 영향에 대해 언급합니다.
Invivyd (Nasdaq: IVVD) a nommé le capital-risqueur Ajay Royan à son conseil d'administration. Royan, fondateur de Mithril Capital, est un actionnaire important à long terme qui a dirigé l'action des actionnaires en 2022, en concentrant Invivyd sur la protection contre les maladies infectieuses virales, en particulier le COVID-19.
L'entreprise vise à faire avancer sa plateforme technologique d'anticorps monoclonaux au-delà de la prévention du COVID-19 vers des médicaments plus évolutifs et de plus grande valeur. La plateforme cible spécifiquement les populations vulnérables, y compris les patients atteints de cancer, les receveurs de greffes d'organes, les individus immunodéprimés et ceux sous traitements immunosuppresseurs.
Royan souligne la nécessité de traiter les maladies endémiques affectant les Américains vulnérables avec la même urgence que l'Opération Warp Speed, mettant en évidence les limites des vaccins et l'impact du long COVID sur ces communautés.
Invivyd (Nasdaq: IVVD) hat den Risikokapitalgeber Ajay Royan in seinen Vorstand berufen. Royan, Gründer von Mithril Capital, ist ein bedeutender langfristiger Aktionär, der 2022 die Aktion der Aktionäre leitete, um Invivyd auf den Schutz vor viralen Infektionskrankheiten, insbesondere COVID-19, zu fokussieren.
Das Unternehmen zielt darauf ab, seine Plattform für monoklonale Antikörpertechnologie über die Prävention von COVID-19 hinaus zu erweitern und in skalierbarere, wertvollere Medikamente zu investieren. Die Plattform richtet sich speziell an gefährdete Bevölkerungsgruppen, einschließlich Krebspatienten, Organtransplantatempfänger, immungeschwächte Personen und solche, die immunsuppressive Therapien erhalten.
Royan betont die Notwendigkeit, endemische Krankheiten, die gefährdete Amerikaner betreffen, mit derselben Dringlichkeit wie Operation Warp Speed anzugehen und hebt die Grenzen von Impfstoffen sowie die Auswirkungen von Long COVID auf diese Gemeinschaften hervor.
- Significant stockholder and experienced venture capitalist joining Board strengthens corporate governance
- Company's monoclonal antibody platform shows potential for expansion beyond COVID-19
- Clear strategic focus on addressing unmet medical needs in vulnerable populations
- Current product portfolio remains to COVID-19 prevention
- Expansion into other therapeutic areas still in planning phase
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan’s investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19.
“We are delighted by Ajay’s return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medical benefit from its core technologies. Invivyd has rapidly re-established the field of monoclonal antibody prevention of COVID-19 and intends to advance into more scalable, higher value medicines that can protect Americans from COVID-19 and other diseases. Invivyd will benefit substantially from Ajay’s acumen as we move forward,” commented Marc Elia, Chairman of Invivyd’s Board of Directors.
“Invivyd is an important company for the future of American medicine. The monoclonal antibody technology platform unique to Invivyd transcends the limits of vaccination to provide high-quality, best-in-class medicines for vulnerable populations,” said Ajay Royan. Mr. Royan added, “Endemic diseases affecting our country’s most vulnerable need to be attacked with the same alacrity, decisiveness, collaborative creativity, and rapid impact that characterized President Trump’s Operation Warp Speed. This is the clarity and urgency with which I and Invivyd look forward to working with critical partners, both in industry and the new administration, to rapidly deliver innovative monoclonal antibody therapies to patients who need them most – people living with cancer, those who have had an organ transplant, those with an immunodeficiency, and individuals on immunosuppressive therapies. COVID-19 continues to kill and disable vast numbers of vulnerable Americans, especially in these communities, for whom the limitations of vaccines and the burdens of long COVID are all too real. And yet they have received neither their due voice in the media mainstream nor the urgent relief they deserve. We can—and therefore must—address their growing, unmet medical need with a holistic approach backed by proven American technology.”
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “estimates,” “intends,” “potential,” “predicts,” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, expectations related to the company’s future prospects, including the company’s efforts to scale medical benefit from its core technologies and advance into more scalable, higher value medicines that can protect Americans from COVID-19 and other diseases; the company’s research and development efforts; the role of Invivyd in the future of American medicine; the future of the COVID-19 landscape and the potential impact of COVID-19 on certain populations; the expectation that Invivyd’s mAb technology platform transcends the limits of vaccination to provide high-quality, best-in-class medicines for vulnerable populations; the expectation to work with critical partners, both in industry and the new administration, to rapidly deliver innovative mAb therapies to patients who need them the most; the company’s competitive position in the market; the anticipated contributions of the company’s directors; the company’s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the company’s discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; whether the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in the regulatory environment; how long the EUA granted by the U.S. FDA for a mAb in the company’s pipeline will remain in effect and whether the EUA is revised or revoked by the U.S. FDA; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; whether the company’s mAb technology platform is able to produce mAbs with broad and durable viral protection along with improved drug properties; whether the company is able to scale medical benefit from its core technologies; changes in expected or existing competition; the company’s reliance on third parties; the complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the outcome of the company’s efforts to work with critical partners; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
What is the significance of Ajay Royan joining IVVD's Board of Directors?
How does IVVD's monoclonal antibody platform differ from traditional vaccines?
What are IVVD's future expansion plans beyond COVID-19 treatment?
Which specific patient groups does IVVD's technology target?
